A suggested positive control for Western blot is 293 cells; suggested positive control for IHC is human breast carcinoma.
C-Jun N-terminal Kinase (JNK) is also known as Mitogen-activated protein kinase (MAPK8). It belongs to the MAPK superfamily of stress-activated protein kinases. MAPKs are Serine-threonine protein kinases that are activated in response to a variety of extracellular stimuli, and mediate signal transduction from the cell surface to the nucleus. JNK is involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. JNK pathways are activated by stress and inflammatory signals. JNK is expressed as ten different isoforms due to differential mRNA splicing. The predominant forms are JNK1 and JNK2.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: c-Jun N-terminal kinase 1; FLJ12099; FLJ33785; JNK-46; JNK1 beta1 protein kinase; JNK3; JNK3 alpha protein kinase; JNK3A; JUN N-terminal kinase; MAP kinase 8; MAPK 10; MAPK 8; MAPK10; MGC50974; mitogen activated protein kinase 8; Mitogen-activated protein kinase 8; mitogen-activated protein kinase 8 isoform JNK1 alpha1; mitogen-activated protein kinase 8 isoform JNK1 beta2; MK10; p493F12; p54 gamma; p54bSAPK; Phospho-JNK; PRKM10; protein kinase mitogen-activated 8; SAPK gamma; SAPK1c; stress-activated protein kinase 1; Stress-activated protein kinase 1c; Stress-activated protein kinase JNK1
Gene Aliases: AI849689; JNK; JNK-46; JNK1; JNK1A2; JNK21B1/2; MAPK8; PRKM8; SAPK1; SAPK1C